Tirzepatide
Human RCTApproved medicineAlso known as: Mounjaro, Zepbound
Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.
Overview
A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and weight management, with strong randomised-trial evidence.
Mechanism
Activates both GIP and GLP-1 receptors, improving insulin secretion and sensitivity while reducing appetite and slowing gastric emptying.
Evidence
Strong: SURPASS and SURMOUNT phase 3 RCT programmes and regulatory approval.
Community-reported information
A prescription medicine dosed per the approved label and a clinician. This app does not restate a personalised schedule.
General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.
Half-life
~5 days (once-weekly dosing)
Storage
Refrigerate 2–8 °C per label.
Commonly reported side effects
- Nausea
- Diarrhoea
- Decreased appetite
- Vomiting
- Constipation
Legal status by region
- USFDA-approved prescription medicine.
- GBMHRA-licensed; prescription only.
- AUTGA-registered; prescription only (Schedule 4).
Legal status changes over time; verify locally before relying on this.
Frequently asked questions
- Is tirzepatide the same as Mounjaro and Zepbound?
- Yes — one active drug, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management.
- How is tirzepatide different from semaglutide?
- Tirzepatide activates two receptors (GIP and GLP-1) rather than GLP-1 alone. Across trials it produced larger average weight loss for many people, though individual responses vary.
- Is tirzepatide banned in sport?
- It is not on the WADA prohibited list, but always verify current status with your anti-doping body.